Urogen Pharma (URGN) Expected to Announce Earnings on Wednesday

Urogen Pharma (NASDAQ:URGN) will likely be releasing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Urogen Pharma to announce earnings of $0.1057 per share and revenue of $89.92 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 10:00 AM ET.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million. On average, analysts expect Urogen Pharma to post ($0.20) EPS for the current fiscal year and $2.94 EPS for the next fiscal year.

Urogen Pharma Stock Performance

NASDAQ:URGN traded down $0.13 during mid-day trading on Tuesday, hitting $34.23. The company had a trading volume of 89,820 shares, compared to its average volume of 835,711. Urogen Pharma has a fifty-two week low of $16.50 and a fifty-two week high of $50.81. The business’s fifty day moving average is $40.19 and its two-hundred day moving average is $31.34. The firm has a market cap of $1.67 billion, a P/E ratio of -17.28 and a beta of 1.57.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on URGN shares. Guggenheim boosted their target price on Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a research report on Wednesday, October 28th. HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Urogen Pharma in a research note on Monday, October 19th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $44.00 target price on shares of Urogen Pharma in a research note on Wednesday, July 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research report on Thursday, October 15th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $52.38.

Insider Buying and Selling at Urogen Pharma

In other Urogen Pharma news, CFO Chris Degnan sold 2,202 shares of the firm’s stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $36.69, for a total value of $80,791.38. Following the transaction, the chief financial officer directly owned 4,561 shares of the company’s stock, valued at $167,343.09. This trade represents a 32.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Jason Smith sold 1,519 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $42.54, for a total transaction of $64,618.26. Following the completion of the transaction, the general counsel directly owned 53,141 shares in the company, valued at approximately $2,260,618.14. This represents a 2.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 65,269 shares of company stock valued at $3,037,646 in the last quarter. Company insiders own 4.80% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.